Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new
approaches to treatment are needed. T-cell therapies are a promising approach for treating …

The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …

Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging
immunotherapeutic approach that is revolutionizing cancer treatment. The impressive …

Chimeric antigen receptor (CAR) T cells have shown promising activity in hematological
malignancies and are being studied for the treatment of multiple myeloma, as well. B-cell …

Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …

Currently available data on chimeric antigen receptor (CAR)-T cell therapy has
demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) …